Related Experiment Videos

Inhibition of tumorigenicity in lung adenocarcinoma cells by c-erbB-2 antisense expression

P Casalini1, S Ménard, S M Malandrin

  • 1Division of Experimental Oncology E, Istituto Nazionale Tumori, Milan, Italy.

Insights

Antisense c-erbB-2 gene transfection reduced lung carcinoma cell tumorigenicity. Lower c-erbB-2 expression correlated with decreased anchorage-independent growth and tumor formation in nude mice.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gene Therapy

Background:

  • The c-erbB-2 oncogene is often overexpressed in lung carcinoma.
  • Calu3 cells, a lung carcinoma cell line, overexpress c-erbB-2.
  • Understanding the role of c-erbB-2 in tumorigenesis is crucial for targeted therapies.

Purpose of the Study:

  • To investigate the effect of antisense (AS) c-erbB-2 gene constructs on the tumorigenic properties of Calu3 lung carcinoma cells.
  • To determine the correlation between c-erbB-2 expression levels and tumor development.
  • To analyze the stability of AS c-erbB-2 DNA inserts in tumor cells.

Main Methods:

  • Stable transfection of Calu3 cells with different AS c-erbB-2 cDNA constructs.
  • Analysis of c-erbB-2 RNA and protein levels in transfected clones.
  • Assessment of in vitro tumorigenic properties, including anchorage-independent growth.
  • Evaluation of in vivo tumorigenicity in nude mice (tumor take).
  • Genetic analysis of primary tumors to assess AS c-erbB-2 DNA insert stability.

Main Results:

  • Two clones, AS F1 (low expressor) and AS B12 (high expressor), and a polyclonal line (Calu3/AS 5') were established.
  • Calu3/AS 5' and AS F1 showed reduced c-erbB-2 RNA and protein levels compared to parental cells.
  • Anchorage-independent growth and tumor take were significantly reduced in cells with lower c-erbB-2 expression.
  • Primary tumor cells lost the AS c-erbB-2 DNA insert but retained the G418 resistance gene.

Conclusions:

  • A correlation exists between c-erbB-2 overexpression and enhanced tumorigenicity in Calu3 lung carcinoma cells.
  • Downregulation of c-erbB-2 via antisense technology can significantly inhibit tumor growth and development.
  • These findings support the potential of targeting c-erbB-2 for lung cancer therapy.

Related Concept Videos